From Fragmented Resources to National Integration: A Strategic Pathway and Implementation Framework for the Transformation of Taiwan’s Biotechnology Industry

2026年4月29日

Amid the ongoing reshaping of global geopolitics and intensifying competition in the biotechnology sector, Taiwan’s biotech industry stands at a critical inflection point—shifting from a “technology-driven” model toward a “value-driven” paradigm. Despite the steady accumulation of R&D capabilities over the past two decades, the industry has struggled to translate technological strengths into global economic value. This is largely due to fragmented resources, अस्पष्ट market positioning, and discontinuities in commercialization capabilities—an issue increasingly reflected in the performance of many publicly listed biotech companies in capital markets.

From a strategic consulting perspective, Taiwan should abandon the “fully integrated, all-in-one company” development model and instead adopt a “hybrid development model” centered on system integration. By promoting a “National Biotech Team” strategy, Taiwan can establish cross-company and cross-disciplinary collaboration platforms to fundamentally address resource misallocation.

1. Resource-Based Perspective: The Trap of “Small but Complete”

From the lens of Resource-Based Theory (RBT), a firm’s competitive advantage derives from resources that are scarce, inimitable, and non-substitutable. However, most Taiwanese biotech firms have long fallen into the “small but complete” trap—attempting to build full capabilities across the entire value chain, including early-stage R&D, clinical trials, regulatory affairs, and commercialization.

Under constraints in capital, talent, and regulatory expertise, this model leads to resource dilution. Companies fail to develop deep core competencies in any single segment while becoming operationally rigid due to bloated organizational structures. Consequently, when faced with the highly capital-intensive nature of drug development, extended R&D cycles and financing gaps often force companies into becoming contract research organizations (CROs) or engaging in low-value licensing-out deals, thereby losing access to downstream value capture.

2. Core Structural Gap: Lack of a Commercialization System

The fundamental challenge facing Taiwan’s biotech sector is not a lack of innovation (supply side), but rather the absence of a robust commercialization system.

Drug development is inherently a highly specialized integration process. Current bottlenecks are evident in two key dimensions:

Clinical and Regulatory Gap: Taiwan lacks sufficient talent with hands-on experience in executing multinational, multi-regional clinical trials (MRCTs). This results in inefficiencies in aligning clinical data quality with international regulatory standards such as those of the FDA and EMA.
Market Access Barrier: Many local biotech executives lack deep understanding of health economics, pricing mechanisms, and reimbursement systems in target markets. Combined with reluctance to delegate authority to professional management, even successfully developed drugs often fail to enter global supply chains—becoming effectively “abandoned innovations.”

Thus, success in drug development should not be defined merely by achieving milestones such as Phase III readouts or regulatory approval, but by post-commercialization revenue generation and market penetration.

3. Global Benchmarking: Defining Taiwan’s Strategic Position

To clarify Taiwan’s transformation pathway, it is essential to benchmark against two dominant global models:

United States Model (Market-Driven Specialization)
The U.S. biotech ecosystem is characterized by a mature venture capital market and highly specialized division of labor. For example, Moderna focuses on mRNA platform innovation and early-stage development, while large pharmaceutical companies such as Pfizer handle large-scale clinical trials and global commercialization. This model thrives on market-driven specialization, reinforced by mergers, acquisitions, and strategic alliances.
China Model (State-Driven Integration)
China adopts a top-down approach, leveraging regulatory reforms led by the National Medical Products Administration (NMPA) and substantial industrial funding to drive large-scale expansion. Companies such as BeiGene and Hengrui have achieved integrated capabilities across R&D, clinical development, and commercialization. While efficient, this model is highly dependent on policy support and thus institutionally sensitive.

Taiwan, however, cannot fully replicate either model—lacking both the scale of the U.S. market and the state-driven capital intensity of China.

4. Taiwan’s Optimal Path: System Integration via a “National Biotech Team”

Taiwan’s most viable strategy lies in combining its high-quality medical research foundation with the agility of its SME ecosystem, while transforming the government’s role into that of a system integrator.

To move from “resource fragmentation” to “national integration,” policy must shift beyond traditional subsidy mechanisms toward platform-building and organizational coordination:

Centralized Clinical Infrastructure
Integrate major medical centers and research institutions to establish a unified clinical trial database and standardized operating procedures.
MRCT Integration Accelerator
Create a dedicated agency to support multinational clinical trials, offering legal advisory, regulatory alignment, and IRB coordination, thereby reducing costs and risks for individual firms.

5. Policy Transformation: From Subsidy Provider to Strategic Integrator

The government should transition from a passive R&D sponsor to an active risk capital allocator and system orchestrator:

Precision Investment Strategy
Utilize national development funds and academia-industry partnerships to support key technological segments, prioritizing globally competitive platform-based biotech companies.
Commercialization Platforms
Establish an international market access office to assist domestic firms in entering Southeast Asia, the Middle East, Europe, and the U.S., including pricing strategy, regulatory pathways, and distribution networks.

6. Industrial Restructuring: Focus, Alliances, and Scale

Policy tools should also encourage structural optimization:

Incentivize Strategic Focus
Through tax incentives and evaluation systems, encourage companies to divest non-core activities.
Virtual Integration Model
Promote alliances between R&D-focused biotech firms and pharmaceutical companies with strong clinical and commercial capabilities.
M&A and Consolidation
Relax regulatory constraints on mergers and acquisitions, offer tax benefits, and encourage consolidation among complementary firms to achieve economies of scale and compete globally.

7. Conclusion: From Technology Provider to Value Chain Leader

The global biotech competition has shifted from breakthroughs in individual drugs to competition among national innovation systems. If Taiwan continues to maintain a fragmented industrial structure, it will struggle to gain strategic positioning within global value chains.

The transformation toward a “National Biotech Team” is not merely a survival strategy—it is a pathway to defining Taiwan’s role in the future global life sciences landscape. Through effective resource allocation, regulatory harmonization with international standards, and strategic collaboration between government and industry, Taiwan has the potential to evolve from a technology provider into a key player in the global value chain.

This transformation represents a fundamental institutional reform—and in this race, time favors those who act decisively.

ブログに戻る